Literature DB >> 24975544

The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Takako Nagai1, Kyoko Nitta, Megumi Kanasaki, Daisuke Koya, Keizo Kanasaki.   

Abstract

Both angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker have been recognized as renin-angiotensin system (RAS) inhibitors. These two RAS inhibitors are rarely recognized as drugs with distinct pharmacological effects in the clinic or most clinical trials. Some preclinical basic research and clinical trials indicate that ACE-I might display superior organ-protective effects, especially anti-fibrotic effects. Such anti-fibrotic effects of ACE-I could be associated with an endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP). In this review, we focused on the anti-fibrotic effects of RAS inhibition and the endogenous anti-fibrotic peptide AcSDKP.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24975544     DOI： 10.1007/s10157-014-1000-3

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


  114 in total

1.  Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits.

Authors:  Wutao Zeng; Weiyan Chen; Xiuyu Leng; Jian Gui He; Hong Ma
Journal:  Biochem Biophys Res Commun       Date:  2009-08-26       Impact factor: 3.575

Review 2.  Pathophysiology of the aging kidney and therapeutic interventions.

Authors:  Keizo Kanasaki; Munehiro Kitada; Daisuke Koya
Journal:  Hypertens Res       Date:  2012-10-18       Impact factor: 3.872

3.  Nicorandil inhibits angiotensin-II-induced proliferation of cultured rat cardiac fibroblasts.

Authors:  Jer-Young Liou; Hong-Jye Hong; Li-Chin Sung; Hung-Hsing Chao; Po-Yuan Chen; Tzu-Hurng Cheng; Paul Chan; Ju-Chi Liu
Journal:  Pharmacology       Date:  2011-02-22       Impact factor: 2.547

Review 4.  Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE).

Authors:  Kenneth E Bernstein; Xiao Z Shen; Romer A Gonzalez-Villalobos; Sandrine Billet; Derick Okwan-Duodu; Frank S Ong; Sebastien Fuchs
Journal:  Curr Opin Pharmacol       Date:  2010-12-02       Impact factor: 5.547

5.  Effects of benazepril on cardiac fibrosis in STZ-induced diabetic rats.

Authors:  Qian Li; Yi Wang; Shu-zhen Sun; Yong-jie Tian; Ming-hua Liu
Journal:  Acta Cardiol       Date:  2010-08       Impact factor: 1.718

6.  Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy.

Authors:  S C W Tang; J C K Leung; L Y Y Chan; A A Eddy; K N Lai
Journal:  Kidney Int       Date:  2007-11-21       Impact factor: 10.612

7.  Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice.

Authors:  Sebastien Fuchs; Hong D Xiao; Justin M Cole; Jonathan W Adams; Kristen Frenzel; Annie Michaud; Hui Zhao; George Keshelava; Mario R Capecchi; Pierre Corvol; Kenneth E Bernstein
Journal:  J Biol Chem       Date:  2004-02-02       Impact factor: 5.157

Review 8.  The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy.

Authors:  Claire E Hills; Paul E Squires
Journal:  Cytokine Growth Factor Rev       Date:  2011-07-14       Impact factor: 7.638

Review 9.  Ace revisited: a new target for structure-based drug design.

Authors:  K Ravi Acharya; Edward D Sturrock; James F Riordan; Mario R W Ehlers
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

Review 10.  Brain renin angiotensin in disease.

Authors:  M Ian Phillips; Edilamar Menezes de Oliveira
Journal:  J Mol Med (Berl)       Date:  2008-04-02       Impact factor: 4.599
View more
  2 in total

Review 1.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

2.  Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.

Authors:  Kyoko Nitta; Sen Shi; Takako Nagai; Megumi Kanasaki; Munehiro Kitada; Swayam Prakash Srivastava; Masakazu Haneda; Keizo Kanasaki; Daisuke Koya
Journal:  Biomed Res Int       Date:  2016-03-20       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.